Vented multi-dose ocular fluid delivery system

Information

  • Patent Grant
  • 12097145
  • Patent Number
    12,097,145
  • Date Filed
    Friday, December 18, 2020
    3 years ago
  • Date Issued
    Tuesday, September 24, 2024
    2 months ago
  • Inventors
  • Original Assignees
    • BAUSCH + LOMB IRELAND LIMITED
  • Examiners
    • Weng; Kai H
    • Del Priore; Alessandro R
    Agents
    • Perilla Knox & Hildebrandt LLP
    • Groff; Bradley K.
    • Davy-Jow; Stephanie L.
Abstract
A device for delivery of a precise amount of pharmaceutical fluid to the eye is provided. The device includes an ampoule for storing a liquid and an aperture through which the liquid is discharged. The device further includes a vibrating membrane that includes a needle which protrudes from the membrane and extends to the aperture to form a needle valve. The needle valve provides hermetic closure of the aperture to enable preservative-free storage of the pharmaceutical fluid in the device. The system further includes an electromagnetic transducer to shift the membrane back and forth in order to discharge liquid through the nozzle. Finally, the system further includes a vent to permit air to enter the ampoule as fluid is ejected from the ampoule. Preferably this vent includes a filter to prevent ingress of microbes or other contaminants to the ampoule.
Description
FIELD OF THE INVENTION

This invention relates to topical ocular delivery of ophthalmic medications.


BACKGROUND

Currently, pharmaceutical fluids are typically delivered to the eye surface using a drop bottle. This method has multiple drawbacks: (1) Patients cannot aim well and often miss the eye; (2) Volume of a drop from a bottle is not well-defined and is too large (on the order of 50 μL) for the tear film on the cornea to absorb it—the tear film can hold no more than about 7 μL; (3) Very often patients blink during the drop delivery, so that part of the drop lands on the eyelid, and the rest is wiped off the cornea.


SUMMARY

We have developed a device that addresses these problems by (1) delivery of a precise amount of fluid; (2) with a micro-dose that the tear film can hold (<10 uL); (3) deliver it within the blink time (˜100 ms), and (4) using an optical aiming onto the cornea for precise self-administration.


For convenient aiming, the fluid ejector should be placed close to the eye, but not touch the eyelashes or eyebrow. Therefore, with reference to FIG. 1, the device 102 should be in the range of approximately L=1-10 cm from the eye, or more optimally 2-6 cm. On this figure, 102 is the fluid ejector, 104 is the emitted fluid stream and 106 is the patient's eye.


The cornea is about D=12 mm in diameter, i.e. 6 mm in radius. To ensure that the fluid is delivered approximately to the middle of the cornea, the jet 104 should not deflect under gravity by more than about half the cornea radius, i.e. no more than about h=3 mm. As shown in FIG. 1, vertical deflection h of the projectile ejected horizontally with velocity v over a distance L is: h=g*L/(2 v2). To ensure that vertical deflection does not exceed h, horizontal jet velocity should exceed v=L*(g/2 h)0.5. For L=5 cm, g=9.8 m/s2, h=3 mm, we obtain v=2 m/s. For L=5 cm and h=1 mm, velocity should be about v=3.6 m/s, and for L=10 cm, h=1 mm, velocity v=7.2 m/s. Therefore overall, jet velocity should be in the range of about 1-10 m/s, and more optimally 2-4 m/s. Velocities much higher than those may cause discomfort to the patient and even damage to the cornea.


The stream of fluid will reach the eye within a few milliseconds from the moment of dispensing (t=L/v, in the range of 1-100 ms). As soon as the fluid will touch the cornea, it will trigger the blink reflex, which typically takes about T=100 ms. To prevent the drug being blocked by the eyelid, the fluid should be delivered before the eye closure. For the required volume V to be delivered within the time T with the jet velocity v, the jet cross-sectional area should be S=V/(T*v). Since for a round aperture, S=π*d2/4, its diameter d=(4V/(πT*v))0.5. For example, for v=2 m/s, T=100 ms, V=10 μL, we obtain d=250 μm. For v=1 m/s, d=350 μm, and for v=7 m/s, d=130 μm.


Therefore, the aperture diameter of the ejector should be in the range of approximately 200-600 μm, and more optimally 400-550 μm. Alternatively, several apertures could be used to produce several parallel streams for faster delivery.


Another key attribute of the system is the prevention of microbial ingress to the contained liquid during storage or use. As with any closed system, as liquid is ejected, air should be introduced to replace the ejected volume and thereby balance the pressure (venting). To preclude microbial ingress, the air is introduced via a special inlet preferably having a 0.2 um filter. Ideally, the device should operate such that liquid is ejected through the aperture any time it is opened, thereby preventing the air ingress through it.


An exemplary embodiment is an arrangement for storing and discharging liquid droplets having a housing including a chamber for holding liquid therein and having an intake port connected to an ampoule containing pharmaceutical fluid to be dispensed. The chamber includes a dispensing aperture plate which defines a frontal closure to the chamber and includes an aperture opening therein through which the liquid is discharged forwardly of the housing. The chamber further includes a vibrating membrane secured to the housing in pressure transmitting relation with the liquid in the chamber. The vibrating membrane is formed with a needle which protrudes from its center and extends to the aperture in the opposite side of the chamber, said needle closes the aperture to prevent outflow of liquid from the chamber and ingress of bacteria.


An electromagnetic transducer is attached to the housing, and when energized, pulls the membrane rearward against a spring in the chamber. When the electromagnetic transducer is turned off, the spring returns the membrane to its original position with the valve closed. When the electromagnetic transducer is energized with pulsatile or alternating current, the membrane is consequently oscillated, which in turn generates pressure on the liquid. At the correct frequencies, the pressure is sufficient to eject a stream of liquid from the aperture.


Typical range of frequencies is in a range of 10 Hz to 500 Hz, more optimally 50 to 200 Hz. The diameter of the nozzle, velocity of the fluid ejection, and duration of the electromagnetic burst are preferably optimized to deliver the required amount of fluid within the required amount of time, as described above. Preferably the actuation pulse duration is 250 ms or less, and more preferably it is 100 ms or less. Here ‘actuation pulse duration’ refers to the length of time the electromagnetic transducer is energized so as to pull the needle out of the aperture in a single actuation pulse.


Other kinds of transducer can also be used to drive fluid ejection in this configuration, such as a coin vibration motor.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 shows geometry for delivering fluid to an eye of a patient.



FIG. 2 is an exterior view of an exemplary embodiment of the invention.



FIG. 3A is a cross section view of a first embodiment of the invention.



FIGS. 3B-C show operation of the embodiment of FIG. 3A.



FIGS. 4A-B show an example of venting.



FIG. 5 is a cross section view of a second embodiment of the invention.



FIG. 6 shows a conical spring.





DETAILED DESCRIPTION


FIG. 2 shows a perspective view of a first embodiment of the liquid ejection unit. The fluid ejection unit 200, is specifically but not exclusively suitable for use in delivering preservative-free pharmaceutical liquid to the surface of the eye. Liquid ejection device 200 comprises a thermoplastic body 206 formed with a liquid chamber and connected to a fluid supply ampule 202. The ejection unit includes nozzle 208 through which liquid 210 is dispensed as will explained in greater detail below.



FIG. 3A illustrates a cross-sectional view of the fluid ejection device. As mentioned earlier the fluid ejection device comprises a thermoplastic body 206 defining a chamber 316 connected to the fluid supply ampule 202 containing a fluid 302. The fluid ejection device includes a nozzle 208 through which liquid is ejected. The device further includes a membrane 308 at the opposite end of the chamber from the nozzle. Membrane 308 includes an integral needle 306 such that they are one component. The needle 306 and the membrane 308 are connected to an electromagnetic transducer 310 via a link member 318. Upon application of an electrical pulse to the electromagnetic transducer 310, electric current flows through the coil 312 and a magnetic force is developed which pulls plunger 314 backward against a spring 320.


On FIG. 3A, 304 shows the direction of fluid flow from ampule 202 to chamber 316. Vent tube 404 is described in greater detail below.



FIG. 3B shows the device of FIG. 3A following application of an electrical pulse to electromagnetic transducer 310. It can be seen that as a result from the magnetic force, plunger 314 is pulled into the electromagnetic transducer in the direction indicated by the arrow. Membrane 308 is connected to plunger 314 by linkage member 318 and is also pulled back. FIG. 3C shows the situation when the electromagnetic transducer 310 is de-energized. Here the spring 320 pushes the membrane 308 back to its original position, so the valve is closed and the chamber is hermetically sealed and prevents microbial ingress.


When the electromagnetic transducer 310 is energized with a pulsatile or alternating (AC) current, the oscillating membrane generates pressure in liquid resulting in a stream ejected from the aperture. Typically, the operating frequency is from 10 to 500 Hz and more specifically from 50 to 200 Hz. In an embodiment, the membrane 308 is made of silicon having hardness durometer between 50-70 (shore A), and the displacement of plunger 314 is about 200 um. Since the flow is produced only in the outward direction, it prevents microbial ingress even when the valve is open.


In the example of FIGS. 4A-B, the liquid ejection device includes a venting arrangement to equalize the pressure inside the ampoule 202 with the ambient atmospheric pressure. Here FIG. 4A is a cross section view along line E-E of FIG. 4B.


The venting system of this example includes an air inlet vent tube 404 that is extended beyond the liquid level of fluid 302 in the ampoule 202. It should be noted that the vent tube 404 is above the liquid level in any orientation of the device of FIGS. 4A-B. Vent tube 404 is connected to venting outlet 406, which is open to the atmosphere. In one embodiment, a filter 408 is placed in the venting outlet 406 such that the vented air flowing to the ampoule is filtered to prevent penetration of potential airborne contamination, such as microbes. Filter 408 will filter away particles with size >1 μm (more preferably >0.5 μm, still more preferably >0.2 μm). In this way the system can be isolated from microbial contamination, even though air 402 enters the ampule 202 as fluid is emitted.


In the preceding examples, diaphragm 308 is driven with a solenoid. In the example of FIG. 5, the diaphragm is driven by using a coin vibration motor. More specifically, 306 is a needle connected to a diaphragm 308 as described above. This assembly is overmolded with a magnetic steel pin 510. 502 is a coin vibrator motor (e.g., JINLONG MACHINERY & ELECTRONICS CO., LTD. model #C1026B002F). 504 is a plastic molded component which holds the motor 502 such that it can slide along rails (i.e., it is a motor holder). 506 is a plastic molded component that provides the above-mentioned rail guides for motor holder 504 to slide within. 510 is a magnetic steel pin which is molded into the membrane/needle assembly (308/306). 512 is the housing that holds all the components together.


Needle 306 normally seals the aperture (i.e., the aperture is sealed except when fluid is being emitted), as described in greater detail above. A coin vibration motor has an eccentric weight off its axis of rotation (the axis of rotation is perpendicular to the plane of FIG. 5). Because the weight is off axis, as the motor rotates the unbalanced weight causes the motor to vibrate primarily in the plane of FIG. 5. By placing the coin vibration motor 502 in a plastic motor holder 504 which fits into corresponding rails (in member 506), the coin vibration motor is constrained so it can only move linearly (e.g., left to right on FIG. 5). As a result of this physical constraint, when the motor rotates, it is only allowed to oscillate left to right, rather than to vibrate in a plane. The coin vibration motor is coupled to the diaphragm 308, consequently as the motor oscillates left to right, the diaphragm is also vibrated left to right. The ejected fluid stream is generated in the same manner as described above—i.e., the needle 306 moves back and forth in the aperture to eject the liquid.


In an alternative embodiment, the coin vibration motor 502 can be coupled to the diaphragm via an optional magnet 508. Magnet 508 is fixed to motor holder 504 which is also affixed to the coin vibration motor 502. When the magnet 508 is close to the magnetic steel pin 510, the two latch together and the motor is thereby coupled to the diaphragm. This is an advantageous assembly feature, because the motor can be easily added to the system without the need for tight tolerances and the motor can be added at several different steps of the assembly process.


The example of FIG. 5 includes a disk-shaped spring 320. The spring is slightly deformed out of plane during assembly which serves to transmit force to needle 306. This force or load keeps the needle 306 pressed up against the orifice to close the flow path. Without the spring, the force required to push the needle open is very low and the device will readily leak. Additionally, the spring has a spring constant which is important for ensuring the correct frequency and amplitude of oscillation of the needle when the motor is energized. Also important is that without the spring it is only the stiffness of the diaphragm 308 which applies a load to keep the needle 306 in the closed position. The diaphragm can be made of an elastomer. For most elastomers mechanical properties vary significantly even with modest temperature changes. With the spring 320, a significant portion of the load applied to the needle 306 comes from the spring 320, not the diaphragm 308. Because the mechanical properties of spring steel (e.g., the material of the spring 320) are far more constant for the same temperature change, adding the spring makes the system performance more consistent.


In an alternative embodiment, the disc spring 320 of FIG. 5 is replaced with a conical spring. A conical spring is similar to a conventional compression spring made of wire, but instead of being wound with a constant diameter, the diameter gets progressively smaller so that the spring has the shape of a cone, not a cylinder. See FIG. 6. When a conical spring is fully compressed, the coils nest within each other so the spring can become flat, only being as thick as the diameter of the wire it is wound from. Thus a fully compressed conical spring can fit in a similar form factor as the disc spring 320 of FIG. 5 and can serve the same function. The conical spring is cheaper, and it is easier to get a wide range of spring constants and operating deflections compared to the disc spring, so it is a feature of presently preferred embodiments.


The tip of needle 306 and/or the aperture it engages with can include an anti-microbial material.

Claims
  • 1. An apparatus for delivering a fluid to an eye of a patient, the apparatus comprising: a fluid package comprising a reservoir configured to hold a fluid, an aperture, and a needle configured to seal the aperture when fluid is not being ejected through the aperture;wherein the fluid package comprises a resilient diaphragm configured to provide a mechanical force to hold a tip of the needle in engagement with the aperture when fluid is not being ejected through the aperture;wherein the resilient diaphragm is connected to the needle;an actuator configured to eject the fluid through the aperture by providing a mechanical vibration at least to the needle; anda vent configured to allow air to enter the reservoir as fluid leaves the reservoir.
  • 2. The apparatus of claim 1, further comprising a particle filter configured to remove particles larger than 0.2 μm from air that enters the reservoir via the vent.
  • 3. The apparatus of claim 1, wherein the actuator includes an electromagnetic solenoid.
  • 4. The apparatus of claim 1, wherein the actuator includes a coin vibration motor.
  • 5. The apparatus of claim 1, wherein the fluid package comprises a resilient spring configured to provide an additional mechanical force to hold the tip of the needle in engagement with the aperture when fluid is not being ejected through the aperture.
  • 6. The apparatus of claim 1, wherein the apparatus is configured to deliver a dose volume of 10 μl or less.
  • 7. The apparatus of claim 1, wherein a diameter of the aperture is in a range between 200 μm and 600 μm.
  • 8. The apparatus of claim 1, wherein a velocity of fluid ejected from the aperture is in a range from 1 m/s to 10 m/s.
  • 9. The apparatus of claim 1, wherein an actuation pulse duration is 250 ms or less.
  • 10. The apparatus of claim 1, wherein a repetition rate of actuation pulses is in a range from 10 Hz to 500 Hz.
  • 11. The apparatus of claim 1, wherein the needle has a tip that engages with the aperture, and wherein the tip comprises an anti-microbial material.
  • 12. The apparatus of claim 1, wherein the aperture comprises an anti-microbial material.
  • 13. The apparatus of claim 1, wherein the aperture is in a front wall of the reservoir and wherein the diaphragm is in a rear wall of the reservoir.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional patent application 62/951,903, filed on Dec. 20, 2019, and hereby incorporated by reference in its entirety. This application claims the benefit of U.S. provisional patent application 63/049,582, filed on Jul. 8, 2020, and hereby incorporated by reference in its entirety. This application claims the benefit of U.S. provisional patent application 63/011,800, filed on Apr. 17, 2020, and hereby incorporated by reference in its entirety. This application claims the benefit of U.S. provisional patent application 63/049,110, filed on Jul. 7, 2020, and hereby incorporated by reference in its entirety. This application is a continuation in part of U.S. application Ser. No. 16/811,879, filed on Mar. 6, 2020, and hereby incorporated by reference in its entirety.

US Referenced Citations (293)
Number Name Date Kind
3640274 Costello Feb 1972 A
3779245 Windsor Dec 1973 A
3812854 Michaels et al. May 1974 A
3861386 Harris et al. Jan 1975 A
3934585 Maurice Jan 1976 A
3970250 Drews Jul 1976 A
3976072 Walker Aug 1976 A
4159803 Cameto et al. Jul 1979 A
4300546 Kruber Nov 1981 A
4334531 Reichl et al. Jun 1982 A
4338576 Takahashi et al. Jul 1982 A
4344744 Schuster et al. Aug 1982 A
4352459 Berger et al. Oct 1982 A
4465234 Maehara et al. Aug 1984 A
4632311 Nakane et al. Dec 1986 A
4655393 Berger Apr 1987 A
4793339 Matsumoto et al. Dec 1988 A
4850534 Takahashi et al. Jul 1989 A
4882150 Kaufman Nov 1989 A
4952581 Bito et al. Aug 1990 A
4961345 Tsuruoka et al. Oct 1990 A
4976259 Higson et al. Dec 1990 A
4981625 Rhim et al. Jan 1991 A
5025957 Ranalletta Jun 1991 A
5171306 Vo Dec 1992 A
5232363 Meller Aug 1993 A
5368582 Bertera Nov 1994 A
5370317 Weston Dec 1994 A
5487378 Robertson et al. Jan 1996 A
5549249 Foster et al. Aug 1996 A
5624057 Lifshey Apr 1997 A
5627611 Scheiner May 1997 A
5630793 Rowe May 1997 A
5657926 Toda Aug 1997 A
5692651 Fuchs Dec 1997 A
5811443 DeSantis, Jr. et al. Sep 1998 A
5828394 Khuri-Yakub et al. Oct 1998 A
5938117 Ivri Aug 1999 A
5958342 Gamble et al. Sep 1999 A
5960224 Sanada et al. Sep 1999 A
6024717 Ball et al. Feb 2000 A
6062212 Davison et al. May 2000 A
6065623 Hierzer et al. May 2000 A
6095376 Hennemann et al. Aug 2000 A
6196218 Voges Mar 2001 B1
6232129 Wiktor May 2001 B1
6273092 Nolan Aug 2001 B1
6302101 Py Oct 2001 B1
6419663 Harrold Jul 2002 B2
6467476 Ivri et al. Oct 2002 B1
RE38077 Cohen et al. Apr 2003 E
6543442 Gonda et al. Apr 2003 B2
6629646 Ivri Oct 2003 B1
6730066 Bennwik et al. May 2004 B1
6758837 Péclat et al. Jul 2004 B2
6869275 Dante et al. Mar 2005 B2
7066398 Borland et al. Jun 2006 B2
7105357 Kalkum et al. Sep 2006 B1
7201732 Anderson et al. Apr 2007 B2
7314938 Shen et al. Jan 2008 B2
7571722 Wuttke et al. Aug 2009 B2
7745460 Shen et al. Jun 2010 B2
7790743 Shen et al. Sep 2010 B2
7874467 Pardes Jan 2011 B2
7883031 Collins, Jr. et al. Feb 2011 B2
7928122 Shen et al. Apr 2011 B2
8012136 Collins, Jr. et al. Sep 2011 B2
8048047 Domash Nov 2011 B2
8056766 Grevin Nov 2011 B2
8128606 Anderson et al. Mar 2012 B2
8133210 Al-Abdulla et al. Mar 2012 B2
8144399 Steenblik et al. Mar 2012 B2
8168655 Gadek et al. May 2012 B2
8273307 Eickhoff et al. Sep 2012 B2
8367701 Burnier et al. Feb 2013 B2
8398001 Borland et al. Mar 2013 B2
8435544 Mitra et al. May 2013 B2
8544462 Papania et al. Oct 2013 B2
8545463 Collins, Jr. et al. Oct 2013 B2
8592450 Gadek et al. Nov 2013 B2
8629111 Acheampong et al. Jan 2014 B2
8633162 Acheampong et al. Jan 2014 B2
8642556 Acheampong et al. Feb 2014 B2
8648048 Acheampong et al. Feb 2014 B2
8684980 Hunter et al. Apr 2014 B2
8685930 Acheampong et al. Apr 2014 B2
8722728 Wong et al. May 2014 B2
8733935 Ballou, Jr. et al. May 2014 B2
8863998 Painchaud et al. Oct 2014 B2
8927574 Burnier Jan 2015 B2
8927921 Nelms et al. Jan 2015 B1
8936021 Collins, Jr. Jan 2015 B2
9039666 Voss et al. May 2015 B2
9068566 Ivri Jun 2015 B2
9085553 Zeller et al. Jul 2015 B2
9087145 Ballou, Jr. et al. Jul 2015 B2
9186690 Scanlon et al. Nov 2015 B2
9216174 Shen et al. Dec 2015 B2
9238532 Decock et al. Jan 2016 B2
9248191 Acheampong et al. Feb 2016 B2
9353088 Burnier May 2016 B2
9447077 Burnier et al. Sep 2016 B2
9597230 Haffner et al. Mar 2017 B2
9676525 Greiner-Perth et al. Jun 2017 B2
9700686 Gavini et al. Jul 2017 B2
9801757 Voss et al. Oct 2017 B2
9808825 Aguilar Nov 2017 B2
9867933 Pardes et al. Jan 2018 B2
9890141 Burnier Feb 2018 B2
10073949 Ballou, Jr. et al. Sep 2018 B2
10105720 Decock et al. Oct 2018 B2
10124000 Shen et al. Nov 2018 B2
10154923 Hunter et al. Dec 2018 B2
10174017 deLong et al. Jan 2019 B2
10314740 Kraft Jun 2019 B2
10624781 Ivri Apr 2020 B2
11278448 Palanker et al. Mar 2022 B2
20010035184 Schuler et al. Nov 2001 A1
20010036424 Takahashi et al. Nov 2001 A1
20010036449 Garst Nov 2001 A1
20020078947 Gumaste Jun 2002 A1
20020124843 Skiba et al. Sep 2002 A1
20020158196 Berggren et al. Oct 2002 A1
20020161344 Peclat et al. Oct 2002 A1
20020185125 Klimowicz et al. Dec 2002 A1
20020190079 Hamamoto Dec 2002 A1
20030052573 Wischnewskiy Mar 2003 A1
20030065294 Pickup et al. Apr 2003 A1
20030071071 Garcia et al. Apr 2003 A1
20030140921 Smith et al. Jul 2003 A1
20040039355 Gonzalez et al. Feb 2004 A1
20040050861 Lisec et al. Mar 2004 A1
20040138630 Al-Abdulla et al. Jul 2004 A1
20040163645 Connelly et al. Aug 2004 A1
20040173642 Clifford et al. Sep 2004 A1
20040204674 Anderson et al. Oct 2004 A1
20040215157 Peclat et al. Oct 2004 A1
20040256487 Collins, Jr. et al. Dec 2004 A1
20040263567 Hess et al. Dec 2004 A1
20050001981 Anderson et al. Jan 2005 A1
20050006417 Nicol et al. Jan 2005 A1
20050107832 Bernabei May 2005 A1
20050172962 Gumaste et al. Aug 2005 A1
20050207917 Koerner et al. Sep 2005 A1
20050240162 Chen et al. Oct 2005 A1
20050261641 Warchol et al. Nov 2005 A1
20060065677 Py et al. Mar 2006 A1
20060069358 Gerondale Mar 2006 A1
20060147313 Zengerle et al. Jul 2006 A1
20060210604 Dadey et al. Sep 2006 A1
20070051362 Sullivan et al. Mar 2007 A1
20070088267 Shekalim Apr 2007 A1
20070088268 Edwards Apr 2007 A1
20070102455 Stark May 2007 A1
20070119969 Collins, Jr. et al. May 2007 A1
20070195151 Anderson et al. Aug 2007 A1
20070268340 Dacquay et al. Nov 2007 A1
20070295332 Ziegler et al. Dec 2007 A1
20080039807 Pine Feb 2008 A1
20080202514 Kriksunov et al. Aug 2008 A1
20080214940 Benaron et al. Sep 2008 A1
20080233053 Gross et al. Sep 2008 A1
20080247264 Gabl et al. Oct 2008 A1
20080257911 Choi et al. Oct 2008 A1
20090060793 Eickhoff et al. Mar 2009 A1
20090114742 Collins, Jr. May 2009 A1
20090134235 Ivri May 2009 A1
20090182291 Eilat Jul 2009 A1
20090192443 Collins, Jr. Jul 2009 A1
20090212127 Reynolds et al. Aug 2009 A1
20090212133 Collins, Jr. Aug 2009 A1
20090223513 Papania et al. Sep 2009 A1
20100001090 Neergaard et al. Jan 2010 A1
20100005903 Beavis Jan 2010 A1
20100013352 Pletner et al. Jan 2010 A1
20100044460 Sauzade Feb 2010 A1
20100072301 Cater Mar 2010 A1
20100072302 Cater Mar 2010 A1
20100076388 Cater Mar 2010 A1
20100147899 Nardi Jun 2010 A1
20100186738 Kobayashi et al. Jul 2010 A1
20100222752 Collins, Jr. Sep 2010 A1
20100236545 Kern Sep 2010 A1
20100295420 Wierach Nov 2010 A1
20100326431 Yu Dec 2010 A1
20110074247 Hohlfeld et al. Mar 2011 A1
20110102735 Gupta et al. May 2011 A1
20110106025 Hall et al. May 2011 A1
20110146670 Gallem et al. Jun 2011 A1
20110284579 Pardes et al. Nov 2011 A1
20110293452 Kim et al. Dec 2011 A1
20120017898 Moller Jan 2012 A1
20120062840 Ballou, Jr. et al. Mar 2012 A1
20120070467 Ballou, Jr. et al. Mar 2012 A1
20120143152 Hunter et al. Jun 2012 A1
20120179122 Eilat et al. Jul 2012 A1
20120197219 Scanlon et al. Aug 2012 A1
20120304929 Ivri Dec 2012 A1
20130002095 Van Der Linden Jan 2013 A1
20130017283 Zemel et al. Jan 2013 A1
20130025038 Frey et al. Jan 2013 A1
20130053042 Tanikawa et al. Feb 2013 A1
20130079733 Burt et al. Mar 2013 A1
20130118619 Loth et al. May 2013 A1
20130140225 Decock et al. Jun 2013 A1
20130150812 Hunter et al. Jun 2013 A1
20130152796 Pawl Jun 2013 A1
20130153677 Leen et al. Jun 2013 A1
20130164436 Yagi et al. Jun 2013 A1
20130172830 Hunter et al. Jul 2013 A1
20130206857 Ivri Aug 2013 A1
20130299607 Wilkerson et al. Nov 2013 A1
20130345672 Ferreri et al. Dec 2013 A1
20140088524 Marx Mar 2014 A1
20140113946 Abad Apr 2014 A1
20140157956 Date et al. Jun 2014 A1
20140171490 Gross et al. Jun 2014 A1
20140187969 Hunter et al. Jul 2014 A1
20140214024 Eichler Jul 2014 A1
20140224267 Levitz et al. Aug 2014 A1
20140242022 Vehige et al. Aug 2014 A1
20140249491 Ballou, Jr. et al. Sep 2014 A1
20140257172 Yalamanchili Sep 2014 A1
20140274910 Cumberlidge et al. Sep 2014 A1
20140276054 Hossack et al. Sep 2014 A1
20140285121 Balogh et al. Sep 2014 A1
20140323931 Avni Oct 2014 A1
20140336596 Wochele Nov 2014 A1
20140336618 Wilkerson et al. Nov 2014 A1
20150018781 Rinderknect et al. Jan 2015 A1
20150035180 Shen et al. Feb 2015 A1
20150036219 Shen et al. Feb 2015 A1
20150040891 Avni Feb 2015 A1
20150086397 Ma Mar 2015 A1
20150097050 Ciervo Apr 2015 A1
20150139973 Steinfeld et al. May 2015 A1
20150144128 Hijlkema et al. May 2015 A1
20150209174 Abreu Jul 2015 A1
20150209178 Blakey et al. Jul 2015 A1
20150238689 Shimizu Aug 2015 A1
20150256730 Shen et al. Sep 2015 A1
20150260179 Hatton Sep 2015 A1
20150276994 Shen et al. Oct 2015 A1
20150308421 Vogt Oct 2015 A1
20150328151 Ballou, Jr. et al. Nov 2015 A1
20150352297 Stedman Dec 2015 A1
20160107180 Decock et al. Apr 2016 A1
20160120833 Wan et al. May 2016 A1
20160129467 Ciardella May 2016 A1
20160199225 Ivri Jul 2016 A1
20160199230 Doshi et al. Jul 2016 A1
20160213866 Tan Jul 2016 A1
20160263314 Pardes et al. Sep 2016 A1
20160296367 Ivri Oct 2016 A1
20160354559 Gavini et al. Dec 2016 A1
20160368009 Hatton Dec 2016 A1
20170028626 Delrot et al. Feb 2017 A1
20170136484 Wilkerson et al. May 2017 A1
20170138357 Kondo et al. May 2017 A1
20170151088 Ballou, Jr. et al. Jun 2017 A1
20170156927 Richter et al. Jun 2017 A1
20170182510 Wilkerson et al. Jun 2017 A1
20170187969 Kitamori et al. Jun 2017 A1
20170274159 Gavini et al. Sep 2017 A1
20170344714 Ballou, Jr. et al. Nov 2017 A1
20180085251 Hunter et al. Mar 2018 A1
20180108275 Newberry et al. Apr 2018 A1
20180116871 Hunter et al. May 2018 A1
20180207030 Ivri Jul 2018 A1
20180229247 Laidler Aug 2018 A1
20180236466 Laidler Aug 2018 A1
20180297053 Buckland et al. Oct 2018 A1
20190053945 Hunter et al. Feb 2019 A1
20190074086 Ballou, Jr. et al. Mar 2019 A1
20190099071 Ehrmann Apr 2019 A1
20190314195 Ivri Oct 2019 A1
20190314196 Ivri et al. Oct 2019 A1
20190314197 Ivri et al. Oct 2019 A1
20190314198 Ivri et al. Oct 2019 A1
20200022416 Alarcon Jan 2020 A1
20200197218 Newell et al. Jun 2020 A1
20200246182 Ivri Aug 2020 A1
20200281768 Quintana et al. Sep 2020 A1
20200315842 Palanker et al. Oct 2020 A1
20200330267 Li et al. Oct 2020 A1
20210128350 Ivri et al. May 2021 A1
20210220169 Ivri Jul 2021 A1
20210322209 Ivri Oct 2021 A1
20210322210 Ivri Oct 2021 A1
20220039998 Ivri Feb 2022 A1
20220125631 Tanchulev et al. Apr 2022 A1
20220160542 Palanker et al. May 2022 A1
20220192874 Ivri Jun 2022 A1
Foreign Referenced Citations (31)
Number Date Country
103118642 May 2013 CN
104146816 Nov 2014 CN
104582647 Apr 2015 CN
204813955 Dec 2015 CN
107530509 Jan 2018 CN
0622035 Nov 1994 EP
0622035 Mar 1999 EP
1493410 Jan 2005 EP
3055480 Jan 1999 JP
2007531577 Nov 2007 JP
2013535250 Sep 2013 JP
10-1258025 Apr 2013 KR
10-2013-0054352 May 2013 KR
1994020875 Jan 1995 WO
1996000050 Jan 1996 WO
WO-9600050 Jan 1996 WO
2001046134 Jun 2001 WO
2002072169 Sep 2002 WO
2010078428 Jul 2010 WO
2012009706 Jan 2012 WO
WO-2013076682 May 2013 WO
2013090459 Jun 2013 WO
2013090468 Jun 2013 WO
2013155201 Oct 2013 WO
2013158967 Dec 2013 WO
2016115050 Jul 2016 WO
2016164830 Oct 2016 WO
WO-2018136618 Jul 2018 WO
2018227190 Dec 2018 WO
2019113483 Jun 2019 WO
2020010116 Jan 2020 WO
Non-Patent Literature Citations (28)
Entry
Abidi et al., “Lifilegrast: A Novel Drug for Treatment of Dry Eye Disease”, Journal of Pharmacology and Pharmacotherapy, 2016, vol. 7, pp. 194-198.
Ali et al., “Glaucoma and Dry Eye”, Ophthalmology, 2009, vol. 116, p. 1232.
Brenton, “CRUK/10/30: TRICON8—Sample collection of ovarian cancer tissues and blood for translational research from patients participating in the CR-UK/MRC ICON8 trial”, 2015, online abstract.
Choi et al., “Generation of Controllable Monodispersed Sprays Using Impulse Jet and Charging Techniques”, Review of Scientific Instruments, 1990, vol. 61, pp. 1689-1693.
Denion et al., “A 5-Minute Interval between Two Dilating Eye Drops Increases Their Effect”, Jul. 19, 2017, Optometry and Vision Science, vol. 94, pp. 838-844.
Electronic Tutorials, “Linear Solenoid Actuator”, 2016 [online]; [Retrieved on Oct. 17, 2022], Retrieved from the Internet [URL: https://www.electronics-tutorials.ws/io/io_6.html].
Elert, Glenn, “Spherical mirrors”, The Physics Hypertextbook, 2021 [online]; [Retrieved on Oct. 17, 2022], Retrieved from the Internet [URL: https://physics.info/mirrors/].
Gannon, Megan, “The Best Length for Eyelashes, According to Science”, Feb. 24, 2015 [online]; [Retrieved on Oct. 17, 2022], Retrieved from the Internet [URL: https://www.livescience.com/49934-optimal-length-for-eyelashes-discovered.html].
Ianchulev et al., “Pharmacodynamic profile of mydriatic agents delivered by ocular piezo-ejection microdosing compared with conventional eyedropper”, 2016, Ther. Deliv., vol. 7, pp. 751-760.
Jow et al., “Design and Optimization of Printed Spiral Coils for Efficient Transcutaneous Inductive Power Transmission”, IEEE Transactions on Biomedical Circuits and Systems, 2007, vol. 1, pp. 193-202.
Kent, Christopher, “Getting Meds onto the Eye, 21st Century Style”, Mar. 15, 2013 [online]; [Retrieved on Aug. 27, 2019], Retrieved from the Internet [URL: https://www.reviewofophthalmology.com/article/getting-meds-onto-the-eye-21st-century-style].
Kompella et al., “ISOPT Clinical Hot Topic Panel Discussion on Ocular Drug Delivery”, 2019, J. Ocul. Pharmacol. Ther., vol. 35, pp. 457-465.
Lallemand et al., “Cyclosporine A Delivery to the Eye: A Comprehensive Review of Academic and Industrial Efforts”, European Journal of Pharmaceutics and Biopharmaceutics, 2017, vol. 117, pp. 14-28.
Lindblad et al., “Production of Uniform-Sized Liquid Droplets”, Journal of Scientific Instruments, 1965, vol. 42, pp. 635-638.
Lux et al., “A Comparative Bioavailability Study of Three Conventional Eye Drops Versus a Single Lyophilisate”, Br. J. Ophthalmol., 2003, vol. 87, pp. 436-440.
Macmillan Online Dictionary, “Stream,” n.d. [online]; [Retrieved on Dec. 13, 2018]; Retrieved from the Internet [URL: https://macmillandictionary.com/dictionary/american/stream_ 1#stream_9].
Marx et al., “Opthalmic Squeeze Dispenser: Eliminating the Need for Additives in Multidose Preservative-Free Eyecare Formulations”, 2017, Drug Development Delivery, vol. 17, pp. 40-44.
Merriam-Webster, “Clamp,” 2019 [online]; [Retrieved on Oct. 25, 2022], Retrieved from the Internet [URL: https://www.merriam-webster.com/dictionary/clamp].
Merriam-Webster, “Collimate,” 2020 [online]; [Retrieved on Oct. 17, 2022], Retrieved from the Internet [URL: https://www.merriam-webster.com/dictionary/collimated].
Merriam-Webster, “Stream,” n.d. [online]; [Retrieved on Dec. 13, 2018], Retrieved from the Internet [URL: https://www.merriam-webster.com/dictionary/stream].
Murube et al., “Classification of Artificial Tears, I: Composition and Properties”, Advanced Experimental Medical Biology, 1998, vol. 438, pp. 693-704.
Murube et al., “Classification of Artificial Tears, II: Additives and Commercial Formulas”, Advanced Experimental Medical Biology, 1998, vol. 438, pp. 705-715.
Oxford Online Dictionary, “Stream,” n.d. [online]; [Retrieved on Dec. 13, 2018]; Retrieved from the Internet [URL: https://en.oxforddictionaries.com/definition/us/stream].
Pronin et al., “Teaching an Old Drug New Tricks: Agonism, Antagonism, and Biased Signaling of Pilocarpine through M3 Muscarinic Acetylcholine Receptor”, 2017, Mol. Pharmacol., vol. 92, pp. 601-612.
Vocabulary.com, “Stream,” n.d. [online]; [Retrieved on Dec. 13, 2018]; Retrieved from the Internet [URL: https://www.dictionary.com/stream].
Birkhoff et al., “New Devices for Dispensing Ophthalmic Treatments May Be the Key to Managing the Life Cycles of Established Products”, 2010, Drug Delivery Technology, vol. 10, pp. 16-21.
International Search Report and Written Opinion dated Jun. 5, 2020 in corresponding International Patent Application No. PCT/US2020/021504 (7 pages).
International Search Report and Written Opinion dated Mar. 29, 2021 in corresponding International Patent Application No. PCT/US2020/066169 (7 pages).
Related Publications (1)
Number Date Country
20210137732 A1 May 2021 US
Provisional Applications (5)
Number Date Country
63049582 Jul 2020 US
63049110 Jul 2020 US
63011800 Apr 2020 US
62951903 Dec 2019 US
62814773 Mar 2019 US
Continuation in Parts (1)
Number Date Country
Parent 16811879 Mar 2020 US
Child 17127584 US